Oral ketamine for children with chronic pain: a pilot phase 1 study.

OBJECTIVE: To assess whether oral ketamine is safe at higher dosages for sedating children and whether it may be an option for the control of chronic pain in children. STUDY DESIGN: A prospective study was performed on 12 children with chronic pain to identify the maximum tolerated dosage of oral ketamine. Participants were given 14 days of oral ketamine, 3 times daily, at dosages ranging from 0.25-1.5 mg/kg/dose. Participants were assessed for toxicity and for pain severity at baseline and on day 14 of treatment. RESULTS: Two participants, both treated at 1.5 mg/kg/dose, experienced dose-limiting toxicities (sedation and anorexia). One participant, treated at 1 mg/kg/dose, opted to stop ketamine treatment due to new pain on treatment. Nine participants completed their course of ketamine treatment. Of these 12 children, 5 experienced improvement in their pain scores, 2 with complete resolution of pain, lasting >4 weeks off ketamine treatment. CONCLUSION: Oral ketamine at dosages of 0.25-1 mg/kg/dose appears to be safe when given for 14 days to children with chronic pain.

High incidence of penicillin resistance among alpha-hemolytic streptococci isolated from the blood of children with cancer.

OBJECTIVES: To survey the susceptibility profiles to several beta-lactam antibiotics and to identify factors related to resistance among blood isolates of alpha-hemolytic streptococci (AHS) obtained from children with cancer. STUDY DESIGN: All pediatric oncology patients with AHS bacteremia occurring from January 1996 through June 1999 at one cancer center were identified. Isolates were categorized based on the minimum inhibitory concentration as susceptible, intermediate, or resistant to several beta-lactam antibiotics. Demographics and potential factors related to antibiotic resistance were obtained from the medical record. RESULTS: Thirty-eight AHS isolates were obtained from 33 patients. Penicillin susceptibility testing revealed that only 8 (21%) isolates were susceptible, 16 (42%) were intermediate, and 14 (37%) were resistant. All 14 of the penicillin-resistant isolates were also resistant to the 3 cephalosporins tested. Ceftriaxone and ceftazidime were the most active cephalosporins. Antibiotic resistance correlated with the recent use of systemic antibiotics, number of prior infectious episodes, and species type. CONCLUSIONS: Blood culture isolates of AHS obtained from children with cancer are frequently resistant to beta-lactam antibiotics. These results indicate that clinically relevant AHS isolates should be tested for antibiotic susceptibility and that beta-lactam antibiotics may not be optimal empiric therapy for fever and neutropenia in children with cancer who have a high risk of AHS infections.